Information & Commentary

The FDA announced five more peptides which will be under review for potential 503A compounding.

Eli Lilly filed six federal lawsuits on August 12, 2026, four against research-use-only sellers, over retatrutide. What was alleged, the argument about RUO labeling, and where the drug stands.

FDA’s Pharmacy Compounding Advisory Committee (PCAC) Peptide Recommendations

With the July 23–24 PCAC meeting just days away, the battle over seven peptides is reaching its climax

by Krysia

Three positive screening results, two laboratories and one unanswered question: what is actually inside the vial?

by Krysia

Jeff Cohen discusses future enforcement, pharmaceutical competition and the evolution of the peptide market.

by Krysia

Jeff Cohen, health law attorney and co-founder of the American Peptide Association explains clinician responsibilities, peptide sourcing and why PUO is growing.

by Krysia

Interview with Jeff Cohen, health law attorney and co-founder of the American Peptide Association

by Krysia